TR

Entrada Therapeutics IncNASDAQ TRDA Stock Report

Last reporting period 30 Sep, 2024

Updated 08 Nov, 2024

Last price

Market cap $B

0.573

Micro

Exchange

XNAS - Nasdaq

TRDA Stock Analysis

TR

Uncovered

Entrada Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

92/100

Moderate score

Market cap $B

0.573

Dividend yield

Shares outstanding

31.395 B

Entrada Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 130 full-time employees. The company went IPO on 2021-10-29. The firm's EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its EEV Platform, Entrada is building a development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular diseases, immunology, oncology and diseases of the central nervous system. The firm's lead oligonucleotide programs include ENTR-601-44 targeting Duchenne muscular dystrophy (DMD), and a follow-on program targeting myotonic dystrophy type 1 (DM1). DMD is a monogenic X-linked disease caused by mutations in the DMD gene.

View Section: Eyestock Rating